112 related articles for article (PubMed ID: 4037737)
1. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI
Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of elliptinium in advanced renal cell carcinoma.
Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of elliptinium in advanced breast cancer.
Rouësse JG; Le Chevalier T; Caille P; Mondesir JM; Sancho-Garnier H; May-Levin F; Spielmann M; De Jager R; Amiel JL
Cancer Treat Rep; 1985 Jun; 69(6):707-8. PubMed ID: 4016774
[TBL] [Abstract][Full Text] [Related]
4. [Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)].
Rougier P; Ychou M; Droz JP
Bull Cancer; 1988; 75(10):979-81. PubMed ID: 2851337
[TBL] [Abstract][Full Text] [Related]
5. Elliptinium: phase II study in advanced measurable breast cancer.
Treat J; Greenspan A; Rahman A; McCabe MS; Byrne PJ
Invest New Drugs; 1989 Jul; 7(2-3):231-4. PubMed ID: 2793378
[TBL] [Abstract][Full Text] [Related]
6. Elliptinium acetate in metastatic breast cancer--a phase II study.
Buzdar AU; Hortobagyi GN; Esparza LT; Holmes FA; Ro JS; Fraschini G; Lichtiger B
Oncology; 1990; 47(2):101-4. PubMed ID: 2314820
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
Piot G; Droz JP; Theodore C; Ghosn M; Rouëssé J; Amiel JL
Oncology; 1988; 45(5):371-2. PubMed ID: 3412745
[TBL] [Abstract][Full Text] [Related]
8. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C
Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).
Einzig AI; Gralla RJ; Leyland-Jones BR; Kelsen DP; Cibas I; Lewis E; Greenberg E
Cancer Invest; 1985; 3(3):235-41. PubMed ID: 4005651
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of 9-hydroxy-2N-methylellipticinium acetate.
Clarysse A; Brugarolas A; Siegenthaler P; Abele R; Cavalli F; de Jager R; Renard G; Rozencweig M; Hansen HH
Eur J Cancer Clin Oncol; 1984 Feb; 20(2):243-7. PubMed ID: 6538489
[TBL] [Abstract][Full Text] [Related]
11. 2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study.
Tura S; Mandelli F; Mazza P; Cimino G; Anselmo AP; Amadori S
Chemioterapia; 1984 Apr; 3(2):79-82. PubMed ID: 6532540
[TBL] [Abstract][Full Text] [Related]
12. [2 N methyl 9 hydroxy-ellipticine in treatment of metastatic breast cancers (author's transl)].
Rouëssé J; Huertas D; Sancho-Garnier H; Le Chevalier T; Amiel JL; Brulé G; Tursz T; Mondésir JM
Bull Cancer; 1981; 68(5):437-41. PubMed ID: 7037078
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of metastatic renal cancer in adults with elliptinium acetate].
Amiel JL; Rouessé J; Droz JP; Caille P; Travagli JP; Théodore C; Le Chevalier T; Ducret JP; Bidart M; Garnier HS
Presse Med; 1984 Jun; 13(25):1555-7. PubMed ID: 6234539
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of elliptinium acetate salvage treatment of advanced breast cancer.
Rouëssé J; Spielmann M; Turpin F; Le Chevalier T; Azab M; Mondésir JM
Eur J Cancer; 1993; 29A(6):856-9. PubMed ID: 8484977
[TBL] [Abstract][Full Text] [Related]
15. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
Juret P; Heron JF; Couette JE; Delozier T; Le Talaer JY
Cancer Treat Rep; 1982 Nov; 66(11):1909-16. PubMed ID: 7139636
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
[No Abstract] [Full Text] [Related]
17. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
Schulman P; Davis RB; Rafla S; Green M; Henderson E
Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
[No Abstract] [Full Text] [Related]
18. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
19. Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
Booth BW; Weiss RB; Korzun AH; Wood WC; Carey RW; Panasci LC
Cancer Treat Rep; 1985; 69(7-8):919-20. PubMed ID: 3893695
[No Abstract] [Full Text] [Related]
20. [Randomized trial of elliptinium acetate and tamoxifen in the treatment of inoperable hepatocellular carcinoma].
Jouanolle H; Delamaire D; Deugnier Y; Lhéry D; Simon M; Brissot P; Bourel M
Gastroenterol Clin Biol; 1986 Feb; 10(2):185-7. PubMed ID: 3009255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
